ATE71410T1 - Tumorspezifische monoklonale antikoerper. - Google Patents

Tumorspezifische monoklonale antikoerper.

Info

Publication number
ATE71410T1
ATE71410T1 AT85300610T AT85300610T ATE71410T1 AT E71410 T1 ATE71410 T1 AT E71410T1 AT 85300610 T AT85300610 T AT 85300610T AT 85300610 T AT85300610 T AT 85300610T AT E71410 T1 ATE71410 T1 AT E71410T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
tumor
specific monoclonal
relates
diagnostic procedures
Prior art date
Application number
AT85300610T
Other languages
English (en)
Inventor
Michael G Hanna Jr
Martin V Haspel
Herbert C Hoover Jr
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24300700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE71410(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Application granted granted Critical
Publication of ATE71410T1 publication Critical patent/ATE71410T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85300610T 1984-01-31 1985-01-30 Tumorspezifische monoklonale antikoerper. ATE71410T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57553384A 1984-01-31 1984-01-31
EP85300610A EP0151030B1 (de) 1984-01-31 1985-01-30 Tumorspezifische monoklonale Antikörper

Publications (1)

Publication Number Publication Date
ATE71410T1 true ATE71410T1 (de) 1992-01-15

Family

ID=24300700

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85300610T ATE71410T1 (de) 1984-01-31 1985-01-30 Tumorspezifische monoklonale antikoerper.

Country Status (15)

Country Link
EP (1) EP0151030B1 (de)
JP (2) JPH0759518B2 (de)
AT (1) ATE71410T1 (de)
AU (2) AU589351B2 (de)
CA (1) CA1340781C (de)
DE (1) DE3585093D1 (de)
DK (1) DK171896B1 (de)
ES (1) ES8802621A1 (de)
GR (1) GR850179B (de)
HU (1) HU209519B (de)
IE (1) IE58859B1 (de)
IL (1) IL74156A (de)
NZ (1) NZ210867A (de)
PT (1) PT79894B (de)
ZA (1) ZA85689B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3319751A1 (de) * 1983-05-31 1984-12-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur gewinnung von gegen tumorantigene gerichteten monoklonalen antikoerpern und diese enthaltende arzneimittel
US6294172B1 (en) 1983-08-12 2001-09-25 Dade Behring Marburg Gmbh Monoclonal antibodies with specificity for membrane-associated antigens
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5552291A (en) * 1985-10-09 1996-09-03 Kyowa, Hakko Kogyo Co., Ltd. Anti-human pulmonary adenocarcinoma specific monoclonal antibody
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
EP0222360A3 (de) * 1985-11-12 1989-03-15 Biotherapeutics Inc. Verfahren zur Herstellung von einem patientspezifischen zytotoxischen Reagenz und Zubereitung
JPS62207298A (ja) * 1986-03-06 1987-09-11 Kyowa Hakko Kogyo Co Ltd 抗ヒト胃癌単クロ−ン性抗体
JPH06100843B2 (ja) * 1986-06-23 1994-12-12 キヤノン株式会社 絶縁性磁性乾式現像剤
NZ222166A (en) * 1986-10-14 1991-03-26 Bunge Australia Monoclonal antibodies against equine chorionic gonadotrophin (ecg), cell-lines, assays, ecg purification and pharmaceutical compositions
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
EP0328578B1 (de) * 1987-07-02 1996-05-08 Akzo Nobel N.V. Von mca 16-88 erkanntes antigen
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
WO1990015625A1 (en) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
WO1991016629A1 (en) * 1990-04-12 1991-10-31 Akzo N.V. Ctaa 28a32, the antigen recognized by mca 28a32
JPH05507924A (ja) * 1990-07-03 1993-11-11 アクゾ・エヌ・ヴエー 免疫反応性化合物
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
DE69229829D1 (de) * 1991-05-16 1999-09-23 Perimmune Holdings Inc Tumorspezifischer monoklonaler antikörper 81av78
IL103758A (en) * 1991-12-13 1998-07-15 Akzo Nv Tumor specific monoclonal antibodies
JPH06113831A (ja) * 1992-04-08 1994-04-26 Dev Center For Biotechnol ハイブリドーマおよびその抗体
EP0650735A3 (de) * 1993-07-09 1999-04-14 Akzo Nobel N.V. Kit und Verfahren zum Vorziehen
ATE421328T1 (de) 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
JP2017502983A (ja) * 2013-10-02 2017-01-26 スリ テクノロジーズ エルティーディー． 不均一な腫瘍を処置するための患者特異的免疫療法
EP3409297A1 (de) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4322879A (en) * 1978-01-11 1979-07-19 Massachusetts General Hospital, The Producing antibodies
DE3211356A1 (de) * 1982-03-27 1983-09-29 Behringwerke Ag, 3550 Marburg Zell-hybrid, verfahren zu seiner herstellung sowie seine verwendung
JPS59137497A (ja) * 1983-01-20 1984-08-07 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
JPS58201994A (ja) * 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells

Also Published As

Publication number Publication date
EP0151030A2 (de) 1985-08-07
JPH0759518B2 (ja) 1995-06-28
IL74156A0 (en) 1985-04-30
AU589351B2 (en) 1989-10-12
GR850179B (de) 1985-05-23
ES539987A0 (es) 1988-09-16
HU209519B (en) 1994-06-28
IE850192L (en) 1985-07-31
EP0151030A3 (en) 1987-11-25
AU635511B2 (en) 1993-03-25
AU3799285A (en) 1985-08-08
PT79894A (en) 1985-02-01
IL74156A (en) 1990-08-31
NZ210867A (en) 1989-01-06
JPS60260597A (ja) 1985-12-23
DK40885D0 (da) 1985-01-30
DK171896B1 (da) 1997-08-04
JPH06315395A (ja) 1994-11-15
ES8802621A1 (es) 1988-09-16
CA1340781C (en) 1999-10-12
JP2516731B2 (ja) 1996-07-24
DK40885A (da) 1985-10-25
IE58859B1 (en) 1993-11-17
AU4736789A (en) 1990-05-03
EP0151030B1 (de) 1992-01-08
ZA85689B (en) 1986-04-30
PT79894B (en) 1986-10-23
DE3585093D1 (de) 1992-02-20
HUT36859A (en) 1985-10-28

Similar Documents

Publication Publication Date Title
DE3585093D1 (de) Tumorspezifische monoklonale antikoerper.
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
EP0256714A3 (de) Kombinationstherapie mit Verwendung von Antitumor-Monoklonalen Antikörpern und/oder Immunotoxinen mit Interleukin-2
DK0712307T3 (da) Fremgangsmåder til B-cellepopulationsregulering
EP0610201A4 (de) Für menschlichen tumornekrose-faktor spezifische monoklonale und chimäre antikörper.
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
DE68924983D1 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
EP0584267A4 (de) Tumorspezifischer monoklonaler antikörper 81av78.
ZA884777B (en) Antigen recognized by mca 16 88
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
Ferrone et al. Active Specific Immunotherapy of Malignant Melanoma with Anti‐idiotypic Monoclonal Antibodies
DE3784364D1 (de) Tumorassoziiertes antigen.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee